Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334735 · ClinicalTrials.gov registry record · Phase 2
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
A Phase 2 study, sponsored by Nina Bhardwaj.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02334735 is a Phase 2 study that has completed, run by Nina Bhardwaj. The registered enrollment target is 36 participants.
The verdict
NCT02334735, a Phase 2 study, has completed, sponsored by Nina Bhardwaj.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subjects with melanoma in complete clinical remission.
Interventions
- BIOLOGICAL Poly-ICLC
- BIOLOGICAL DC Vaccine
- BIOLOGICAL Montanide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02334735
The ClinicalTrials.gov registry entry for NCT02334735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nina Bhardwaj, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Poly-ICLC is the first listed.
NCT02334735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02334735 about?
NCT02334735 is a clinical study titled "A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence". Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subject...
What is the current status of trial NCT02334735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-07-01. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT02334735?
The interventions under investigation include: Poly-ICLC (BIOLOGICAL), DC Vaccine (BIOLOGICAL), Montanide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02334735?
This trial is sponsored by Nina Bhardwaj, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.